Juan I. Marin

Medellin, ANT, Colombia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Immune-mediated adverse events following atezolizumab and bevacizumab in a multinational Latin American cohort of unresectable hepatocellular carcinoma.

Immune-mediated adverse events following atezolizumab and bevacizumab in a multinational Latin American cohort of unresectable hepatocellular carcinoma.

Journal: Oncotarget

Published: May 19, 2025

Breaking Barriers for Intensive Care Admission in Patients With Advanced HCC on Immunotherapy.

Breaking Barriers for Intensive Care Admission in Patients With Advanced HCC on Immunotherapy.

Journal: Liver international : official journal of the International Association for the Study of the Liver

Published: February 17, 2025

Hepatic Recompensation Before Systemic Therapy for Hepatocellular Carcinoma Yields Comparable Survival to Compensated Cirrhosis.

Hepatic Recompensation Before Systemic Therapy for Hepatocellular Carcinoma Yields Comparable Survival to Compensated Cirrhosis.

Journal: Liver international : official journal of the International Association for the Study of the Liver

Published: January 02, 2025

Latin American expert opinion letter on the feasibility of systemic therapies in combination with locoregional therapies for hepatocellular carcinoma.

Latin American expert opinion letter on the feasibility of systemic therapies in combination with locoregional therapies for hepatocellular carcinoma.

Journal: Annals of hepatology

Published: November 21, 2024

The leading and key role of hepatologists in the multidisciplinary management of patients with hepatocellular carcinoma.

The leading and key role of hepatologists in the multidisciplinary management of patients with hepatocellular carcinoma.

Journal: Annals of hepatology

Published: March 14, 2023

Liver decompensation is a frequent cause of treatment discontinuation and prognostic factor in intermediate-advanced HCC.

Liver decompensation is a frequent cause of treatment discontinuation and prognostic factor in intermediate-advanced HCC.

Journal: Annals of hepatology

Published: February 03, 2023

Genetic Ancestry, Race, and Severity of Acutely Decompensated Cirrhosis in Latin America.

Genetic Ancestry, Race, and Severity of Acutely Decompensated Cirrhosis in Latin America.

Journal: Gastroenterology

Published: December 05, 2022

Lenvatinib as first-line therapy for recurrent hepatocellular carcinoma after liver transplantation: Is the current evidence applicable to these patients?

Lenvatinib as first-line therapy for recurrent hepatocellular carcinoma after liver transplantation: Is the current evidence applicable to these patients?

Journal: World journal of transplantation

Published: May 18, 2020

International and multicenter real-world study of sorafenib-treated patients with hepatocellular carcinoma under dialysis.

International and multicenter real-world study of sorafenib-treated patients with hepatocellular carcinoma under dialysis.

Journal: Liver international : official journal of the International Association for the Study of the Liver

Published: December 28, 2019

Colombian experience in the treatment of hepatitis C with direct-acting antiviral agents.

Colombian experience in the treatment of hepatitis C with direct-acting antiviral agents.

Journal: Medicina

Published: January 30, 2019

An experience of liver transplantation in Latin America: a medical center in Colombia.

An experience of liver transplantation in Latin America: a medical center in Colombia.

Journal: Colombia medica (Cali, Colombia)

Published: August 10, 2013

Showing 1-11 of 11

Last Updated: 09/26/2026